Protalix Biotherapeutics

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Protalix BioTherapeutics excels in Q2 with milestone achievements and revenue growth

Protalix BioTherapeutics delivered strong financial performance in Q2 2023, driven by milestone achievements and revenue growth.
The company's robust balance sheet, successful product launches, and focus on innovation position it well for future success.
While facing challenges in a competitive market, Protalix has opportunities to expand market presence, drive innovation, and enhance shareholder value.
Strategic execution and continued focus on profitability will be key for Protalix to capitalize on opportunities and navigate industry challenges.

Protalix BioTherapeutics navigates mixed Q3 results, eyes pipeline advancements

Protalix BioTherapeutics reported a mixed financial performance in Q3 2023, with revenue fluctuations and cost management efforts impacting the bottom line. The company remains focused on advancing its pipeline candidates and commercial launches to drive future growth and market success.
Despite challenges in revenue streams and cost structures, Protalix demonstrated operational stability and strategic decision-making in navigating market dynamics. The company's strong leadership team, diverse product portfolio, and ongoing clinical programs position it well for future opportunities and growth.
Overall, Protalix BioTherapeutics showcased resilience amidst external events, with a strategic focus on product approvals, cost optimization, and clinical advancements. The company's financial stability, strong cash reserves, and commitment to innovation underscore its competitive position in the biopharmaceutical industry.

Protalix BioTherapeutics reports stellar Q4 performance and growth opportunities

Protalix BioTherapeutics delivered strong financial results in Q4 2023, driven by the successful launch of Elfabrio and cost-saving measures.
Strategic leadership additions and a robust cash position position the company well for future growth and innovation.
While challenges persist in sustaining growth and managing costs, opportunities in new drug development and market expansion offer promising avenues for Protalix.

Protalix BioTherapeutics reports Q1 progress with promising pipeline advancements

Protalix BioTherapeutics navigated revenue challenges with cost management and maintained financial stability through a strong cash position.
Progress in the pipeline with PRX-115's positive Phase I results and upcoming Phase II trial signals potential growth opportunities.
Analyst inquiries underscore the importance of addressing safety concerns, conducting robust trials, and effectively positioning products in a competitive market.

Protalix BioTherapeutics advances PRX-115 for uncontrolled gout treatment

Protalix BioTherapeutics showcased promising results for PRX-115 in uncontrolled gout, with plans for Phase II trial and a focus on renal rare diseases.
Despite a net loss in Q2 2024, the company's strong cash position supports operations and strategic R&D efforts for future growth.
Challenges in financial performance call for cost management strategies, while opportunities lie in clinical advancements and innovative product development.

Protalix BioTherapeutics reports robust Q3 earnings and advances innovative therapies

Protalix BioTherapeutics delivered strong financial performance in Q3 2024, marked by revenue growth, net income, and debt-free status, showcasing operational efficiency.
PRX-115's positive Phase I trial results and upcoming Phase II trial highlight Protalix's commitment to innovation and advancing novel therapies for unmet medical needs.
While facing challenges in regulatory dynamics and competitive landscape, Protalix has opportunities to leverage its strengths in product development and market expansion for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARMIEL, Israel , March 13, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that it does not hold cash deposits or securities at either Silicon Valley Bank or Signature Bank, nor does it have any credit facility or other financial relationship with either institution. The Company maintains a majority of its cash and short-term bank deposits in money center banks in the United States with the remainder deposited in a large financial institution in Israel.

Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

Nuburu Inc

Eos Energy Enterprises

Faraday Future Intelligent Electric

Lucira Health

Troika Media Group

GeneDx Holdings Corp

Cheap penny stocks to watch before next week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week

Protalix BioTherapeutics Inc. (NYSE:PLX ) Q4 2022 Earnings Conference Call February 27, 2023 8:30 AM ET Company Participants Dror Bashan - President, Chief Executive Officer Eyal Rubin - Senior Vice President, Chief Financial Officer Monique Kosse - LifeSci Advisors Conference Call Participants Boobalan Pachaiyappan - HC Wainwright John Vandermosten - Zacks Small Cap Research Operator Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference is being recorded.

Protalix BioTherapeutics (PLX) Q4 2022 Earnings Call Transcript

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Feb. 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2022 and provided a business update on recent corporate and regulatory developments.

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

Protalix and Chiesi received a CHMP nod for PRX-102 (pegunigalsidase alfa). There is also an FDA PDUFA date of May 9, 2023.

Protalix Undervalued On CHMP Recommendation Of PRX-102 For Fabry Disease

- European Commission decision anticipated in beginning of May 2023 - PARMA, Italy and BOSTON and CARMIEL, Israel, Feb. 24, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company, announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX–102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease. "Chiesi and our partners at Protalix are deeply committed to people living with Fabry disease and their families, many of whom experience unmet medical needs," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases.

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

CARMIEL, Israel , Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.   The Company will be hosting an informational booth at the symposium.

Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023

Company to host conference call and webcast at 8:30 a.m. EST. CARMIEL, Israel , Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.

Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023

Shares of plant-derived enzyme therapy concern Protalix BioTherapeutics, Inc. have rallied after its Fabry disease asset PLX-102 received a PDUFA date of May 9, 2023 from the FDA. The company is also anticipating a decision from the EMA on its application sometime in 1H23.

The Prognosis For Protalix BioTherapeutics

CARMIEL, Israel , Jan. 3, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.     January 3, 2023 Dear Protalix Shareholders, 2022 was a strong year for Protalix, and I would like to take a moment to reflect on the significant progress we have made.

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

Akebia Therapeutics

Eiger BioPharmaceuticals

Vaxart

Penny stocks to watch before next year. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 To Watch Before 2023

The Company's Common Stock will continue to trade on the NYSE American CARMIEL, Israel , Dec. 21, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that the Company's management and Board of Directors have decided that it is in the best interest of the Company to voluntarily delist its common stock from the Tel Aviv Stock Exchange (the "TASE"). The Company believes that delisting its common stock from the TASE will allow management to focus better on the Company's primary capital market and reduce its cost of operations as the Company will be subject to only one set of listing rules and regulations.

Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange

CARMIEL, Israel and BOSTON , Dec. 5, 2022 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease. Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors Dror Bashan - President, CEO Eyal Rubin - SVP, CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Operator Greetings, and welcome to the Protalix BioTherapeutics Third Quarter 2022 Financial and Business Results Conference Call.

Protalix BioTherapeutics, Inc. (PLX) Q3 2022 Earnings Call Transcript

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Nov. 14, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2022 and provided a business update on recent corporate and regulatory developments.

Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results

CARMIEL, Israel and BOSTON , Nov. 14, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the resubmission on November 9, 2022 of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for PRX–102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked α-galactosidase-A investigational product candidate.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter 2022 and provide a business update on Monday, November 14, 2022.

Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022

CARMIEL, Israel , Sept. 12, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present in person on Wednesday, September 14, 2022 at 11:00 a.m.

Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference

CARMIEL, Israel , Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company will present at the H.C.

Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Protalix BioTherapeutics Inc. (NYSE:PLX ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors, Investor Relations Dror Bashan - President, CEO and Director Eyal Rubin - Senior VP, CFO, Treasurer and Corporate Secretary Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix Second Quarter 2022 Financial and Business Results Conference Call.

Protalix BioTherapeutics Inc. (PLX) CEO Dror Bashan on Q2 2022 Results - Earnings Call Transcript

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 15, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2022 and provided a business update on recent corporate and regulatory developments.

Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 8, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the second quarter 2022 and provide a business update on Monday, August 15, 2022.

Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022

CARMIEL, Israel , June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors.

Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

CARMIEL, Israel , May 26, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities. The program is supported by Kidneys for Life, a Registered UK Charitable Organization (Manchester, UK), and is taking place May 29, 2022 through May 31, 2022 at the Maritim Hotel and Conference Center, Würzburg Germany.

Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease

Protalix BioTherapeutics Inc. (NYSE:PLX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President & CEO Eyal Rubin - SVP & CFO Conference Call Participants John Vandermosten - Zacks Small Cap Research Operator Good morning, ladies and gentlemen, and welcome to the Protalix First Quarter 2022 Financial and Business Results Conference Call. [Operator Instructions] I do reminder, this conference call is being recorded.

News for Protalix Biotherapeutics Stock (PLX)